Ignite SD
0
Login
Register
Viewing Study NCT00004494
Home
Search
Stocks
Certify Doc
Genes
Clinical Trials
CompTox
DrugMatrix
Open Targets
Products
Support
Bugs
eRecord
Main Search
All Studies
All Organizations
Report Bug
View Study With Definitions
Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004494
Status:
COMPLETED
Last Update Posted:
2022-05-04
First Post:
1999-10-18
Brief Title:
Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
Sponsor:
Stony Brook University
Organization:
Stony Brook University
Overview
Dates
Organization
Conditions
Design
Enrollment
Locations
Outcomes
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
OBJECTIVES
I Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with acute respiratory distress syndrome
II Evaluate the safety and pharmacodynamic activity of this peptide in these patients
Detailed Description:
PROTOCOL OUTLINE
This is a dose escalation study
Patients receive vasoactive intestinal peptide VIP IV over either 6 or 12 hours
Cohorts of 3 patients each receive escalating doses of VIP over either 6 or 12 hours until the maximum tolerated dose is determined
Patients are followed for 30 days
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID
Type
Domain
Link
FD-R-0001488
OTHER_GRANT
FDA Orphan Drug Products
None
SUNY-SB-FDR001488
None
None
None
SUNY-SB-96-077
None
None
None
SUNY-SB-98-2606
None
None
None